Page 82 - Read Online

Lue et al. J Cancer Metastasis Treat 2022;8:11 https://dx.doi.org/10.20517/2394-4722.2021.193 Page 25 of 25

164. Hill BT, Roberts ZJ, Xue A, Rossi JM, Smith MR. Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen
receptor T-cell therapy in refractory diffuse large B-cell lymphoma. Bone Marrow Transplant 2020;55:1184-7. DOI PubMed PMC
165. Funk CR, Wang S, Chen KZ, et al. PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to
enhance antitumor cytotoxicity. Blood 2022;139:523-37. DOI PubMed PMC
166. Shadman M, Yeung C, Redman M, et al. Safety and efficacy of third generation CD20 targeted CAR-T (MB-106) for treatment of
relapsed/refractory B-NHL and CLL. Blood 2021;138:3872. DOI
167. Baird JH, Frank MJ, Craig J, et al. CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory
large B-cell lymphoma. Blood 2021;137:2321-5. DOI PubMed PMC
168. Zah E, Lin MY, Silva-Benedict A, Jensen MC, Chen YY. T Cells expressing CD19/CD20 bispecific chimeric antigen receptors
prevent antigen escape by Malignant B cells. Cancer Immunol Res 2016;4:498-508. DOI PubMed PMC
169. Tong C, Zhang Y, Liu Y, et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma.
Blood 2020;136:1632-44. DOI PubMed PMC
170. Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma
(SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. The Lancet Haematology 2020;7:e511-22. DOI
PubMed
171. Pfreundschuh M, Trümper L, Kloess M, et al; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-
weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the
NHL-B2 trial of the DSHNHL. Blood 2004;104:634-41. DOI
172. Khurana A, Mwangi R, Nowakowski GS, et al. Impact of organ function-based clinical trial eligibility criteria in patients with diffuse
large B-Cell lymphoma: who gets left behind? J Clin Oncol 2021;39:1641-9. DOI PubMed PMC